Routes of
administration Oral CAS Number 63619-84-1 ChemSpider 45471 | ATC code none PubChem CID 50139 Molar mass 453.57 g/mol | |
 | ||
Legal status In general: uncontrolled | ||
Trioxifene (LY-133,314) was a selective estrogen receptor modulator (SERM) with competitive binding activity against estradiol for estrogen receptor-alpha (ERα) and antagonistic activity against ERα-mediated gene expression, that was under preclinical and clinical development by Eli Lilly and Company for breast cancer and prostate cancer, but was abandoned.
References
Trioxifene Wikipedia(Text) CC BY-SA